HK1081647A1 - N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses - Google Patents

N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses

Info

Publication number
HK1081647A1
HK1081647A1 HK06101566.6A HK06101566A HK1081647A1 HK 1081647 A1 HK1081647 A1 HK 1081647A1 HK 06101566 A HK06101566 A HK 06101566A HK 1081647 A1 HK1081647 A1 HK 1081647A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
monoclonal antibodies
truncated amyloid
beta monoclonal
Prior art date
Application number
HK06101566.6A
Other languages
English (en)
Inventor
Marc Hubert Mercken
Marc Maria Pierre Vandermeeren
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1081647A1 publication Critical patent/HK1081647A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK06101566.6A 2002-09-27 2006-02-06 N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses HK1081647A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2002/011062 WO2004029629A1 (fr) 2002-09-27 2002-09-27 Anticorps monoclonaux beta-amyloide n-11 tronques, compositions, methodes et utilisations
PCT/EP2003/010092 WO2004029630A1 (fr) 2002-09-27 2003-09-09 Anticorps monoclonaux tronques reconnaissant les peptides beta-amyloides n-11, compositions, procedes et applications

Publications (1)

Publication Number Publication Date
HK1081647A1 true HK1081647A1 (en) 2006-05-19

Family

ID=32039081

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06101566.6A HK1081647A1 (en) 2002-09-27 2006-02-06 N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses

Country Status (14)

Country Link
US (2) US9329189B2 (fr)
EP (1) EP1546734B1 (fr)
JP (3) JP2006513988A (fr)
CN (2) CN101367875B (fr)
AU (1) AU2003266378B2 (fr)
CA (1) CA2498058C (fr)
CY (1) CY1117387T1 (fr)
DK (1) DK1546734T3 (fr)
ES (1) ES2560853T3 (fr)
HK (1) HK1081647A1 (fr)
HU (1) HUE028331T2 (fr)
PT (1) PT1546734E (fr)
SI (1) SI1546734T1 (fr)
WO (2) WO2004029629A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO2004029629A1 (fr) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. Anticorps monoclonaux beta-amyloide n-11 tronques, compositions, methodes et utilisations
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20060054174A (ko) * 2003-03-28 2006-05-22 센토코 인코포레이티드 항-아밀로이드 항체, 조성물, 방법 및 용도
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
EP2298807A3 (fr) 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Anticorps anti peptide amyloide beta, et leurs procedes d' utilisation
US20060246075A1 (en) * 2004-09-29 2006-11-02 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
ES2259270B1 (es) * 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
RU2551782C2 (ru) * 2005-12-12 2015-05-27 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
UA94734C2 (ru) * 2006-03-30 2011-06-10 Глаксо Груп Лимитед ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
EP2043687A4 (fr) * 2006-06-29 2010-03-17 Centocor Ortho Biotech Inc Anticorps anti-amyloides, compositions, procedes et utilisations
PL2046833T3 (pl) * 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
EP2142514B1 (fr) 2007-04-18 2014-12-24 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
KR20150055103A (ko) * 2007-06-12 2015-05-20 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
CA2701790A1 (fr) * 2007-10-05 2009-04-16 Ac Immune S.A. Utilisation d'anticorps anti-amyloides beta humanises dans les maladies oculaires
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
EP2211886A4 (fr) * 2007-10-15 2011-07-27 Centocor Ortho Biotech Inc Anticorps humains anti-amyloïdes, compositions, procédés et utilisations
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009070648A2 (fr) * 2007-11-27 2009-06-04 Medtronic, Inc. Anticorps anti-amyloïde bêta humanisés
CN101463085B (zh) * 2009-01-16 2011-09-14 清华大学 与A-beta寡聚体特异性结合的基因工程单克隆抗体
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
JP6081356B2 (ja) 2010-07-30 2017-02-15 エーシー イミューン エス．エー． 安全で機能的なヒト化抗βアミロイド抗体
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
BR112013023211B1 (pt) 2011-03-16 2022-11-08 Vivoryon Therapeutics N.V. Anticorpo monoclonal, seu uso, composição, linhagem celular, método diagnóstico in vitro e kit
EP2511296A1 (fr) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Anticorps, kit et procédé pour déterminer des peptides amyloïdes
WO2013167153A1 (fr) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
RU2678127C2 (ru) 2012-11-13 2019-01-23 Бионтех Аг Агенты для лечения экспрессирующих клаудин раковых заболеваний
TWI573805B (zh) 2013-05-20 2017-03-11 建南德克公司 抗轉鐵蛋白受體抗體及其使用方法
EP3221362B1 (fr) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anticorps anti-récepteur de transferrine et procédés d'utilisation
CN107250158B (zh) 2014-11-19 2022-03-25 基因泰克公司 抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
WO2016094566A2 (fr) 2014-12-10 2016-06-16 Genentech, Inc. Anticorps dirigés contre les récepteurs de la barrière hématoencéphalique et procédés d'utilisation associés
WO2017079835A1 (fr) 2015-11-09 2017-05-18 The University Of British Columbia Épitopes de la bêta-amyloïde et anticorps associés
CN108350051A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中的N-末端表位及其构象选择性抗体
KR20180085736A (ko) 2015-11-09 2018-07-27 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2019167830A1 (fr) 2018-02-27 2019-09-06 株式会社 島津製作所 ANTICORPS RECONNAISSANT DE MANIÈRE SPÉCIFIQUE L'EXTRÉMITÉ N-TERMINALE DE APP669-x, ET PROCÉDÉ DE DOSAGE IMMUNOLOGIQUE
KR20210100086A (ko) 2018-10-04 2021-08-13 유니버시티 오브 로체스터 혈장 오스몰농도 조작에 의한 글림프 전달의 개선
EP3898667A2 (fr) 2018-12-20 2021-10-27 F. Hoffmann-La Roche AG Fc d'anticorps modifiés et méthodes d'utilisation
US20220137071A1 (en) 2019-03-01 2022-05-05 Shimadzu Corporation Method and kit for measuring app669-711
CN114026109A (zh) 2019-07-05 2022-02-08 株式会社岛津制作所 β淀粉样蛋白的单克隆抗体、和使用该抗体的β淀粉样蛋白相关肽的测定方法
CN116348487A (zh) 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体
CN112540180B (zh) * 2020-11-06 2022-03-29 华中科技大学 用于检测人淀粉样蛋白-β双抗夹心ELISA检测试剂盒
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (fr) 2021-05-24 2022-12-01 Eli Lilly And Company Anticorps anti-amyloïde bêta et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3816111B2 (ja) * 1997-04-09 2006-08-30 インテレクト・ニューロサイエンシズ・インコーポレーテッド β−アミロイド末端に特異的な組換え抗体、それをコードするＤＮＡ及びその使用法
MXPA02001911A (es) * 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
AU2002243391A1 (en) 2000-10-27 2002-06-24 The Johns Hopkins University School Of Medicine Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof
WO2004029629A1 (fr) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. Anticorps monoclonaux beta-amyloide n-11 tronques, compositions, methodes et utilisations
AU2012286021A1 (en) * 2011-07-15 2014-01-16 Janssen Pharmaceutica Nv Monoclonal antibodies specific for beta-amyloid x-37 and uses thereof

Also Published As

Publication number Publication date
JP2014208678A (ja) 2014-11-06
WO2004029630A1 (fr) 2004-04-08
US9329189B2 (en) 2016-05-03
DK1546734T3 (en) 2016-02-08
CN100418984C (zh) 2008-09-17
AU2003266378A1 (en) 2004-04-19
CA2498058A1 (fr) 2004-04-08
SI1546734T1 (sl) 2016-02-29
ES2560853T3 (es) 2016-02-23
AU2003266378B2 (en) 2010-01-21
EP1546734B1 (fr) 2015-11-11
CN1685236A (zh) 2005-10-19
CA2498058C (fr) 2013-02-12
CY1117387T1 (el) 2017-04-26
PT1546734E (pt) 2016-03-01
EP1546734A1 (fr) 2005-06-29
WO2004029629A1 (fr) 2004-04-08
JP2017149719A (ja) 2017-08-31
US9939452B2 (en) 2018-04-10
CN101367875B (zh) 2013-06-12
JP2006513988A (ja) 2006-04-27
HUE028331T2 (en) 2016-12-28
US20060127954A1 (en) 2006-06-15
US20170192016A1 (en) 2017-07-06
JP6420072B2 (ja) 2018-11-07
CN101367875A (zh) 2009-02-18

Similar Documents

Publication Publication Date Title
HK1081647A1 (en) N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
HRP20151252T1 (en) Modified antibody fab fragments
EP1578930A4 (fr) Polypeptides cngh0004, anticorps, compositions, procedes et utilisations
EP1494693A4 (fr) Anticorps specifiques au cripto
HUP0302376A3 (en) Anti-tnf antibodies, compositions, methods and uses
IL158643A (en) Anti-hmg monoclonal antibodies and compositions containing the same
EP1633785A4 (fr) Anticorps monoclonaux humains diriges contre l'antigene protecteur de bacillus anthracis
IL168304A (en) Human monoclonal antibodies against cd25
IL180364A0 (en) Antibodies directed against amyloid-beta peptide and methods using same
SI2206517T1 (sl) Imunopotencirni sestavki,ki obsegajo protitelesa proti PD-L1
IL174304A0 (en) Kid3 and kid3 antibodies that bind thereto
EP1499352A4 (fr) Anticorps anti-interleukine-9 recombinants
HUP0402333A3 (en) Modified anti-tnf alpha antibody
IL206832A0 (en) Antibodies binding an 161p2f10b epitope and uses thereof
EP1637598A4 (fr) Peptide partiel de cd47 et anticorps monoclonal anti-shps-1
EP1699485A4 (fr) Anticorps anti-hydroxylase et utilisations
AU2002359495A8 (en) Anti-tnf antibodies, compositions, methods and uses
IL172510A0 (en) Antibodies and uses thereof
EP1711527A4 (fr) Anticorps specifiques de hla-dr, compositions et methodes associees
ZA200508729B (en) Anti-amyloid antibodies, compositions, methods and uses
EP1539792A4 (fr) Polypeptides cngh0005, anticorps, compositions, methodes et utilisations
EP1633399A4 (fr) Anticorps recombines, compositions et leurs methodes de fabrication et d'utilisation
AU2003237332A8 (en) Anti-relp fusion antibodies, compositions, methods and uses
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
GB0226878D0 (en) Antibodies

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210907